In vitro to in vivo extrapolation and physiologically based modeling of cytochrome P450 mediated metabolism in beagle dog gut wall and liver

Molecular Pharmaceutics

Volumn 10, Issue 4, 2013, Pages 1388-1399

  Heikkinen, Aki T ^a,b   Fowler, Stephen ^b   Gray, Lynn ^c   Li, Jia ^c   Peng, Ying ^c   Yadava, Preeti ^c   Railkar, Aruna ^c   Parrott, Neil ^b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c HOFFMANN LA ROCHE INC   (United States)

Author keywords

ACAT; bioavailability; first pass metabolism; IVIVE; PBPK

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 CYP2B11; CYTOCHROME P450 CYP3A12; DOMPERIDONE; FELODIPINE; NITRENDIPINE; QUINIDINE; SILDENAFIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; ENZYME SUBSTRATE; FEMALE; IMMUNOADSORPTION; IN VITRO STUDY; IN VIVO STUDY; INTESTINE WALL; LIVER; METABOLISM; MOLECULAR MODEL; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CYTOCHROME P-450 CYP2B1; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; DOMPERIDONE; FELODIPINE; HUMANS; INTESTINES; KINETICS; LIVER; NITRENDIPINE; PERMEABILITY; PIPERAZINES; PURINES; QUINIDINE; SULFONES; TISSUE DISTRIBUTION;

EID: 84875764672     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp300692k     Document Type: Article

References (67)

1. Jones, H. M.; Gardner, I. B.; Collard, W. T.; Stanley, P. J.; Oxley, P.; Hosea, N. A.; Plowchalk, D.; Gernhardt, S.; Lin, J.; Dickins, M.; Rahavendran, S. R.; Jones, B. C.; Watson, K. J.; Pertinez, H.; Kumar, V.; Cole, S. Simulation of Human Intravenous and Oral Pharmacokinetics of 21 Diverse Compounds Using Physiologically Based Pharmacokinetic Modelling Clin. Pharmacokinet. 2011, 50, 331-347
2. Zhao, P.; Zhang, L.; Grillo, J. A.; Liu, Q.; Bullock, J. M.; Moon, Y. J.; Song, P.; Brar, S. S.; Madabushi, R.; Wu, T. C.; Booth, B. P.; Rahman, N. A.; Reynolds, K. S.; Gil Berglund, E.; Lesko, L. J.; Huang, S. M. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review Clin. Pharmacol. Ther. 2011, 89, 259-67
3. Peters, S. A. Physiologically-Based Pharmacokinetic (PBPK) Modeling and Simulations: Principles, Methods, and Applications in the Pharmaceutical Industry; John Wiley & Sons, Inc.: Hoboken, NJ, 2012.
4. Huang, S. M.; Rowland, M. The role of physiologically based pharmacokinetic modeling in regulatory review Clin. Pharmacol. Ther. 2012, 91, 542-9
5. Heikkinen, A. T.; Baneyx, G.; Caruso, A.; Parrott, N. Application of PBPK Modeling to Predict Human Intestinal Metabolism of CYP3A Substrates-an Evaluation and Case Study Using GastroPlus Eur. J. Pharm. Sci. 2012, 47, 375-386
6. Hallifax, D.; Houston, J. B. Methodological uncertainty in quantitative prediction of human hepatic clearance from in vitro experimental systems Curr. Drug Metab. 2009, 10, 307-21
7. De Buck, S. S.; Sinha, V. K.; Fenu, L. A.; Nijsen, M. J.; Mackie, C. E.; Gilissen, R. A. H. J. Prediction of Human Pharmacokinetics Using Physiologically Based Modeling: A Retrospective Analysis of 26 Clinically Tested Drugs Drug Metab. Dispos. 2007, 35, 1766-1780
8. Jones, H. M.; Parrott, N.; Jorga, K.; Lave, T. A novel strategy for physiologically based predictions of human pharmacokinetics Clin. Pharmacokinet. 2006, 45, 511-42
9. Rowland, M.; Peck, C.; Tucker, G. Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science Annu. Rev. Pharmacol. Toxicol. 2011, 51, 45-73
10. Naritomi, Y.; Terashita, S.; Kagayama, A.; Sugiyama, Y. Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro Drug Metab. Dispos. 2003, 31, 580-8
11. Watanabe, T.; Kusuhara, H.; Maeda, K.; Shitara, Y.; Sugiyama, Y. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans J. Pharmacol. Exp. Ther. 2009, 328, 652-62
12. Kuentz, M.; Nick, S.; Parrott, N.; Röthlisberger, D. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study Eur. J. Pharm. Sci. 2006, 27, 91-99
13. Parrott, N.; Lukacova, V.; Fraczkiewicz, G.; Bolger, M. B. Predicting pharmacokinetics of drugs using physiologically based modeling-application to food effects AAPS J. 2009, 11, 45-53
14. Heikkinen, A. T.; Friedlein, A.; Lamerz, J.; Jakob, P.; Cutler, P.; Fowler, S.; Williamson, T.; Tolando, R.; Lave, T.; Parrott, N. Mass Spectrometry-Based Quantification of CYP Enzymes to Establish In Vitro-In Vivo Scaling Factors for Intestinal and Hepatic Metabolism in Beagle Dog Pharm. Res. 2012, 29, 1832-1842
15. Gertz, M.; Davis, J. D.; Harrison, A.; Houston, J. B.; Galetin, A. Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations Curr. Drug Metab. 2008, 9, 785-95
16. Boxenbaum, H. Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin J. Pharmacokinet. Biopharm. 1980, 8, 165-76
17. Meuldermans, W.; Hurkmans, R.; Swysen, E.; Hendrickx, J.; Michiels, M.; Lauwers, W.; Heykants, J. On the pharmacokinetics of domperidone in animals and man III. Comparative study on the excretion and metabolism of domperidone in rats, dogs and man Eur. J. Drug Metab. Pharmacokinet. 1981, 6, 49-60
18. Scherling, D.; Karl, W.; Ahr, H. J.; Kern, A.; Siefert, H. M. Biotransformation of nitrendipine in rat, dog, and mouse Arzneimittelforschung 1991, 41, 1009-21
19. Walker, D. K.; Ackland, M. J.; James, G. C.; Muirhead, G. J.; Rance, D. J.; Wastall, P.; Wright, P. A. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man Xenobiotica 1999, 29, 297-310
20. Kuroha, M.; Kayaba, H.; Kishimoto, S.; Khalil, W. F.; Shimoda, M.; Kokue, E. Effect of oral ketoconazole on first-pass effect of nifedipine after oral administration in dogs J. Pharm. Sci. 2002, 91, 868-73
21. Weidolf, L.; Borg, K. O.; Hoffmann, K. J. Urinary metabolites of felodipine, a new vasodilator drug, in man, dog, rat and mouse Xenobiotica 1984, 14, 657-66
22. Kyokawa, Y.; Nishibe, Y.; Wakabayashi, M.; Harauchi, T.; Maruyama, T.; Baba, T.; Ohno, K. Induction of intestinal cytochrome P450 (CYP3A) by rifampicin in beagle dogs Chem. Biol. Interact. 2001, 134, 291-305
23. FDA.Guidance for Industry: Waiver of In Vivo Bioavailabilityand Bioequivalence Studies for Immediate-Release Solid Oral DosageForms Based on a Biopharmaceutics Classification System; Food and Drug Administration: Washington, DC, 2000.
24. Lennernäs, H. Modeling Gastrointestinal Drug Absorption Requires More In Vivo Biopharmaceutical Data: Experience from In Vivo Dissolution and Permeability Studies in Humans Curr. Drug Metab. 2007, 8, 645-657
25. GastroPlus manual, version 8.0; SimulationsPlus: Lancaster, CA, 2012.
26. Heikkinen, A. T.; Korjamo, T.; Lepikkö, V.; Mönkkönen, J. Effects of Experimental Setup on the Apparent Concentration Dependency of Active Efflux Transport in in Vitro Cell Permeation Experiments Mol. Pharmaceutics 2010, 7, 605-617
27. Schinkel, A. H.; Wagenaar, E.; Mol, C. A.; van Deemter, L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs J. Clin. Invest. 1996, 97, 2517-24
28. Shi, Z.; Tiwari, A. K.; Shukla, S.; Robey, R. W.; Singh, S.; Kim, I.-W.; Bates, S. E.; Peng, X.; Abraham, I.; Ambudkar, S. V.; Talele, T. T.; Fu, L.-W.; Chen, Z.-S. Sildenafil Reverses ABCB1- and ABCG2-Mediated Chemotherapeutic Drug Resistance Cancer Res. 2011, 71, 3029-3041
29. Hyafil, F.; Vergely, C.; Du Vignaud, P.; Grand-Perret, T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative Cancer Res. 1993, 53, 4595-4602
30. Agoram, B.; Woltosz, W. S.; Bolger, M. B. Predicting the impact of physiological and biochemical processes on oral drug bioavailability Adv. Drug Delivery Rev. 2001, 50, S41-S67
31. Shimada, T. Factors affecting the microclimate pH in rat jejunum J. Physiol. 1987, 392, 113-27
32. Iwatsubo, T.; Miyamoto, Y.; Sugiyama, Y.; Yuasa, H.; Iga, T.; Hanano, M. Effects of potential damaging agents on the microclimate-pH in the rat Jejunum J. Pharm. Sci. 1986, 75, 1162-1165
33. Zhimin, H. Theoretical effects of molecular dimension and configuration on effective diffusion coefficient of macromolecules in microporous membranes Trans. Tianjin Univ. 1995, 1, 42-47
34. Pang, K. S.; Rostami-Hodjegan, A. Fraction absorbed (Fabs): different connotations and confusion for the literature? Biopharm. Drug Dispos. 2011, 32, 301-2
35. Krause, H. P.; Ahr, H. J.; Beermann, D.; Siefert, H. M.; Suwelack, D.; Weber, H. The pharmacokinetics of nitrendipine. I. Absorption, plasma concentrations, and excretion after single administration of [14C]nitrendipine to rats and dogs Arzneimittelforschung 1988, 38, 1593-9
36. Bäärnhielm, C.; Dahlbäck, H.; SkaÌŠnberg, I. In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man Acta Pharmacol. Toxicol. (Copenhagen) 1986, 59, 113-22
37. Venkatakrishnan, K.; von Moltke, L. L.; Court, M. H.; Harmatz, J. S.; Crespi, C. L.; Greenblatt, D. J. Comparison between Cytochrome P450 (CYP) Content and Relative Activity Approaches to Scaling from cDNA-Expressed CYPs to Human Liver Microsomes: Ratios of Accessory Proteins as Sources of Discrepancies between the Approaches Drug Metab. Dispos. 2000, 28, 1493-1504
38. Proctor, N. J.; Tucker, G. T.; Rostami-Hodjegan, A. Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors Xenobiotica 2004, 34, 151-78
39. Crewe, H. K.; Barter, Z. E.; Rowland Yeo, K.; Rostami-Hodjegan, A. Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter-system extrapolation factors Biopharm. Drug Dispos. 2011, 32, 303-318
40. Chen, Y.; Liu, L.; Nguyen, K.; Fretland, A. J. Utility of Intersystem Extrapolation Factors in Early Reaction Phenotyping and the Quantitative Extrapolation of Human Liver Microsomal Intrinsic Clearance Using Recombinant Cytochromes P450 Drug Metab. Dispos. 2011, 39, 373-382
41. Yang, J.; Jamei, M.; Yeo, K. R.; Tucker, G. T.; Rostami-Hodjegan, A. Prediction of intestinal first-pass drug metabolism Curr. Drug Metab. 2007, 8, 676-684
42. Jamei, M.; Turner, D.; Yang, J.; Neuhoff, S.; Polak, S.; Rostami-Hodjegan, A.; Tucker, G. Population-Based Mechanistic Prediction of Oral Drug Absorption AAPS J. 2009, 11, 225-237
43. Thelen, K.; Coboeken, K.; Willmann, S.; Burghaus, R.; Dressman, J. B.; Lippert, J. Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, Part 1: Oral solutions J. Pharm. Sci. 2011, 100, 5324-5345
44. Gertz, M.; Houston, J. B.; Galetin, A. Physiologically-based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction Drug Metab. Dispos. 2011, 39, 1633-1642
45. Psachoulias, D.; Vertzoni, M.; Butler, J.; Busby, D.; Symillides, M.; Dressman, J.; Reppas, C. An in vitro methodology for forecasting luminal concentrations and precipitation of highly permeable lipophilic weak bases in the fasted upper small intestine Pharm. Res. 2012, 29, 3486-98
46. Klein, S.; Buchanan, N. L.; Buchanan, C. M. Miniaturized Transfer Models to Predict the Precipitation of Poorly Soluble Weak Bases upon Entry into the Small Intestine AAPS PharmSciTech 2012, 13, 1230-5
47. Sinha, V. K.; Snoeys, J.; Osselaer, N. V.; Peer, A. V.; Mackie, C.; Heald, D. From preclinical to human-prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example Biopharm. Drug Dispos. 2012, 33, 111-121
48. Heikkinen, A. T.; Mönkkönen, J.; Korjamo, T. Determination of permeation resistance distribution in in vitro cell monolayer permeation experiments Eur. J. Pharm. Sci. 2010, 40, 132-142
49. Lennernäs, H. Intestinal permeability and its relevance for absorption and elimination Xenobiotica 2007, 37, 1015-1051
50. Fenneteau, F.; Poulin, P.; Nekka, F. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates J. Pharm. Sci. 2010, 99, 486-514
51. Nishimuta, H.; Sato, K.; Yabuki, M.; Komuro, S. Prediction of the intestinal first-pass metabolism of CYP3A and UGT substrates in humans from in vitro data Drug Metab Pharmacokinet. 2011, 26, 592-601
52. Cong, D.; Doherty, M.; Pang, K. S. A new physiologically based, segregated-flow model to explain route-dependent intestinal metabolism Drug Metab. Dispos. 2000, 28, 224-235
53. Pang, K. S.; Chow, E. C. Commentary: theoretical predictions of flow effects on intestinal and systemic availability in physiologically based pharmacokinetic intestine models: the traditional model, segregated flow model, and QGut model Drug Metab. Dispos. 2012, 40, 1869-77
54. Fan, J.; Chen, S.; Chow, E. C.; Pang, K. S. PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism Curr. Drug Metab. 2010, 11, 743-61
55. Takeuchi, T.; Yoshitomi, S.; Higuchi, T.; Ikemoto, K.; Niwa, S.; Ebihara, T.; Katoh, M.; Yokoi, T.; Asahi, S. Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1 Pharm. Res. 2006, 23, 1460-72
56. Thiebaut, F.; Tsuruo, T.; Hamada, H.; Gottesman, M. M.; Pastan, I.; Willingham, M. C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 7735-7738
57. Heykants, J.; Hendriks, R.; Meuldermans, W.; Michiels, M.; Scheygrond, H.; Reyntjens, H. On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration Eur. J. Drug Metab. Pharmacokinet. 1981, 6, 61-70
58. Heykants, J.; Knaeps, A.; Meuldermans, W.; Michiels, M. On the pharmacokinetics of domperidone in animals and man. I. Plasma levels of domperidone in rats and dogs. Age related absorption and passage through the blood brain barrier in rats Eur. J. Drug Metab. Pharmacokinet. 1981, 6, 27-36
59. Soons, P. A.; Breimer, D. D. Stereoselective pharmacokinetics of oral and intravenous nitrendipine in healthy male subjects Br. J. Clin. Pharmacol. 1991, 32, 11-6
60. Hughes, I. E.; Ilett, K. F.; Jellett, L. B. The distribution of quinidine in human blood Br. J. Clin. Pharmacol. 1975, 2, 521-5
61. Kuroha, M.; Shirai, Y.; Shimoda, M. Multiple oral dosing of ketoconazole influences pharmacokinetics of quinidine after intravenous and oral administration in beagle dogs J. Vet. Pharmacol. Ther. 2004, 27, 355-9
62. Roche internal database; F.Hoffmann-La Roche AG: Basel, Switzerland, 2012.
63. Dagenais, C.; Avdeef, A.; Tsinman, O.; Dudley, A.; Beliveau, R. P-glycoprotein deficient mouse in situ blood-brain barrier permeability and its prediction using an in combo PAMPA model Eur. J. Pharm. Sci. 2009, 38, 121-37
64. Kostewicz, E. S.; Carlsson, A. G.; Hanisch, G.; Krumkühler, K.; Nilsson, R. G.; Löfgren, L.; Abrahamsson, B. Comparison of dog and human intestinal fluid and its impact on solubility estimatios Eur. J. Pharm. Sci. 2002, 17, S111
65. Arndt, M.; Chokshi, H.; Tang, K.; Parrott, N. J.; Belli, S.; Schuler, F.; Reppas, C.; Dressman, J. B. Dissolution media simulating the proximal canine gastrointestinal tract in the fasted state Eur. J. Pharm. Biopharm. 2013, 10.1016/j.ejpb.2013.01.010
66. Clarysse, S.; Brouwers, J.; Tack, J.; Annaert, P.; Augustijns, P. Intestinal drug solubility estimation based on simulated intestinal fluids: comparison with solubility in human intestinal fluids Eur. J. Pharm. Sci. 2011, 43, 260-9
67. Gobry, V.; Bouchard, G.; Carrupt, P.-A.; Testa, B.; Girault, H. H. Physicochemical Characterization of Sildenafil: Ionization, Lipophilicity Behavior, and Ionic-Partition Diagram Studied by Two-Phase Titration and Electrochemistry Helv. Chim. Acta 2000, 83, 1465-1474